Source: TimeWerke Videos on YouTube.
Valued at between US$48,000 and US$69,000 (CHF48,000 to CHF69,000 / EUR43,000 and EUR62,000) by Christie’s, the Grönefeld 1941 Remontoire housed in a 39.5mm stainless steel case is one of the fifty unique timepieces offered for sale at the 2019 Only Watch auction that will be held on 9 November in Geneva, Switzerland.
This Grönefeld 1941 Remontoire is equipped with the Calibre G-05 that has an eight seconds remontoire mechanism that delivers a constant force to the escapement resulting in higher isochronism and precision. The action is visible on the dial side at 9 o’clock by way of the blue governor that spins every eight seconds.
Grönefeld 1941 Remontoire for Only Watch 2019. Valued at between US$48,000 and US$69,000 (CHF48,000 to CHF69,000 / EUR43,000 and EUR62,000) by Christie’s (before the Only Watch auction on 9 November 2019). Photo: Only Watch.
The movement is one of the 188 limited edition calibres that are made by Grönefeld but this is a pièce unique, in line with the Only Watch auction, as it features a one-off silver dial with a frosted surface in “vintage-smoked” colours and polished hour markers.
The Only Watch auction is a charity project whereby proceeds from the sales of the timepieces will mostly be donated to the Monegasque Association against Myopathies (Association Monégasque Contre Les Myopathies) for their medical and scientific research activities.
These will support the scientific research to find a cure to Duchenne Muscular Dystrophy, a disease that is, to this day, incurable and affects one boy over 3,000 male births, highlights Prince Albert II of Monaco.
Since the establishment of biennual Only Watch charity auction in 2005, more than EUR35 million has been raised.
The Grönefeld 1941 Remontoire is equipped with the Calibre G-05,one of the 188 limited edition calibres made. Photo: Grönefeld.
“Thanks to the funds raised by Only Watch, the Monegasque Association against Myopathies has been able to set up an international consortium of public and private laboratories focused on the development of new therapeutic approaches such as gene therapy, cell therapy and repair of mutated nucleic acids, in particular by modulating mRNA splicing. Some of these approaches are very promising, some have already been successfully evaluated in man,” says Luis Garcia, scientific advisor of the Monegasque Association against Myopathies.